English
Company introduction
The immunotherapy of cancer has recently achieved unprecedented clinical success in previously untreatable forms of solid malignancy. Elucidation and targeting of inhibitory pathways known as immune checkpoint, which naturally limit the magnitude of specific immunity, has made this possible. Despite the revolutionary success of checkpoint inhibitors at improving cancer outcomes by unleashing latent immunity targeting immunogenic tumors, most people with advanced cancer still fail to respond to treatment. By combining several established technologies in Proprietary combinations, OncoVent is using its technology platform to raise the level of …
View more  +
Enterprise culture
Innovation, Honest, Responsibility and Win-Win
View more  +
Team to introduce
Mr. Li Li, President, Chairman of Board
Mr. Li Li: He was born in 1964, Chinese, without permanent residence abroad, graduated from Chemistry School of Sichuan University with a bachelor’s degree in July 1987. He founded Hepalink in April 1998 and is the current Chairman of Hepalink and OncoVent.
View more  +
Dr. Yuenian Eric Shi, Deputy Chairman&CEO
Dr. Shi (Eric) is a biomedical scientist specializing on cancer research and translational medicine development. Eric was the associate professor and then full Professor of Albert Einstein College of Medicine between 1994-2010, during which, he led twelve national research programs funded by the U.S. National Cancer Institute (NCI)and U.S. Department of Defense (DOD). In 2010, Eric returned to China and became Vice President of the Academy of Clinical Research and Translational Medicine Jiangsu Province. Eric leads three research projects sponsored by China National Science Foundation, and one cancer early diagnosis research sponsored by Nati
View more  +
Dr. Christopher F. Nicodemus,Director
Dr. Nicodemus is the Founder and President of AIT Strategies, Franconia, NH USA providing research & development and business guidance to clients and collaborators working in the field ofclinical immunology and most especially immuno-oncology. He is an innovator inthe area of combinatorial immunotherapy and has multiple issued or pendingpatents associated with OncoVent technology. A Fellow of the American Collegeof Physicians, Dr Nicodemus received his undergraduate and doctoral degreesfrom Harvard College and the State University of New York in Syracuse and completed his clinical and research training at the Brigham and Womens Hospital
View more  +
Partners
Company introduction
Enterprise culture
Team to introduce
Partners

188金宝搏